TP0480066 是一种选择性 topoisomerase II 抑制剂,对 DNA gyrase 和 topo IV 的 IC50 值分别为 1.10 和 62.89 nM,对包括耐药菌株在内的多种细菌均具有良好的活性,同时对 N. gonorrhoeae 也表现出良好的抑制活性,可用于淋病的研究。
产品编号: MS-L44988 CAS No.: 2245693-15-4 分子式: C18H14FN3O5 分子量: 371.32
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

TP0480066 是一种选择性 topoisomerase II 抑制剂,对 DNA gyrase 和 topo IV 的 IC50 值分别为 1.10 和 62.89 nM,对包括耐药菌株在内的多种细菌均具有良好的活性,同时对 N. gonorrhoeae 也表现出良好的抑制活性,可用于淋病的研究。

生物实验数据

生物活性 TP0480066 is a selective topoisomerase II inhibitor with IC50 values of 1.10 and 62.89 nM against DNA gyrase and topo IV, respectively, and exhibits favorable activity against various bacteria, including drug-resistant strains, as well as potent inhibitory activity against N. gonorrhoeae, making it useful for research on gonorrhea.
IC50 & Target TOPO IV:62.89 nM, DNA gyrase:1.10 nM
体外研究
(In Vitro)

TP0480066 (compound 32) (0-2048 μg/mL; 18-24 h) demonstrats favorable antimicrobial activities against various bacterial species including some clinically isolated drug-resistant strains: MRSA (n=24), gPRSP (n=30), and VRE (n=34).
TP0480066 (0-2048 μg/mL; 18-24 h) shows good antibacterial activity against Clostridioides difficile.
TP0480066 (0-2048 μg/mL; 24-48 h) demonstrates potent antibacterial activity to N. gonorrhoeae, including strains with decreased susceptibility or resistance to currently available antimicrobial agents.
TP0480066 (1.25×10-4, 5×10-4 and 2×10-3 µg/mL; 24 h) shows good time-kill activity when concentration up to (or more than) MIC (5×10-4 µg/mL) in N. gonorrhoeae ATCC 49226.

Cell Viability Assay

Cell Line: Clinically isolated Methicillin-resistant S. aureus (24 strains), Vancomycin-resistant enterococci (E. faecium (29 strains) and E. faecalis (5 strains), vanA positive (18 strains), vanB positive (14 strains) and vanA/vanB negative (2 strains)), Genotype penicillin-resistant S. pneumonia (30 strains)
Concentration: 0-2048 μg/mL
Incubation Time: 18-24 h
Result: Showed favorable antimicrobial activities to drug-resistant strains with MIC ranges of 0.03-0.5, 0.015-0.25 and 0.002-0.015 μg/mL for MRSA (n=24), gPRSP (n=30), and VRE (n=34), respectively.

Cell Viability Assay

Cell Line: N. gonorrhoeae ATCC (49226, 43069, BAA-1846, 700717, 700825), N. gonorrhoeae NCTC (13477, 13478, 13479, 13480, 13481, 13482, 13483, 13818, 13821)
Concentration: 0-2048 μg/mL
Incubation Time: 24-48 h
Result: Exhibited significant antimicrobial activities to both N. gonorrhoeae and drug-resistant N. gonorrhoeae (MIC ranges both were ≤0.00012-0.0005 µg/mL)

Cell Viability Assay

Cell Line: N. gonorrhoeae ATCC 49226
Concentration: 1.25×10-4, 5×10-4 and 2×10-3 µg/mL
Incubation Time: 24 h
Result: Reduced the viable N. gonorrhoeae ATCC 49226 counts by more than 3-log10 CFU/mL (99.9%) after 6 h at 4× MIC and after 24 h at the MIC, respectively.
体内研究
(In Vivo)

TP0480066 (100 mg/kg; s.c; once) demonstrates Cmax, Tmax, t1/2, and AUC0-24 h values of 12400 ng/mL, 0.250 h, 6.79 h, 16000 h•ng/mL, respectively.
TP0480066 (1, 3, 10, 30, 100 mg/kg; s.c.; single) inhibits (30, 100 mg/kg) both N. gonorrhoeae ATCC 49226 and NCTC 13479 at 24 h and in a dose-dependent manner in mice.

Animal Model: Female Slc:ICR mice
Dosage: 100 mg/kg
Administration: Subcutaneous injection, once.
Result: 1.19 Pharmacokinetic Parameters of TP0480066 in Female Slc:ICR mice (n=3).
Tmax (h) Cmax (ng/mL) AUC0-24 (ng/mL•h) t1/2 (h)
SC (100 mg/kg) 0.250 12400 16000 6.79
Animal Model: Female BALB/c mice (6-week-old; genital tract infection model)
Dosage: 1, 3, 10, 30 and 100 mg/kg
Administration: Subcutaneous administration; single.
Result: Significantly decreased mean viable cell counts of N. gonorrhoeae ATCC 49226 and NCTC 13479 when at 30, 100 mg/kg.

化学信息

分子量 371.32
分子式 C18H14FN3O5
CAS No. 2245693-15-4

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础